Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | CFTR | P13569 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31589985 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| SCHEMBL2895994 | 0.90 | ALDH1A1 (0.67) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| Methyl Anthranilate SCHEMBL57713 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| Methyl Anthranilate SCHEMBL901249 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| Methyl Anthranilate SCHEMBL29564148 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| Methyl Anthranilate SCHEMBL29444250 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| Methyl Anthranilate SCHEMBL28199302 | 0.83 | ALDH1A1 (0.74) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| SCHEMBL204668 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| SCHEMBL31258869 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HSD17B10CFTRTSHRLMNA | |
| SCHEMBL14828745 | 0.82 | ALDH1A1 (0.58) | ALDH1A1HSD17B10CFTRTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121609673-B | PDE4 inhibitor and preparation method and application thereof | WUYI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-120040757-A | Wear-resistant water-based alkyd resin and preparation method thereof | 山东齐鲁漆业有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-118290987-A | PCB (printed circuit board) inkjet printing anti-diffusion agent and preparation method and using method thereof | 珠海市板明科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-116606491-B | Anti-aging PE material and synthesis process thereof | 广东诚和信新材料有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-114105800-B | Preparation method of 2, 3-diaminomethyl benzoate | 杭州国瑞生物科技有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116606491-A | Anti-aging PE material and synthesis process thereof | 广东诚和信新材料有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | claimed |
| CN-114105800-A | Preparation method of 2, 3-diaminobenzoic acid methyl ester | 杭州国瑞生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-3012256-B1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2018-08-08 | — | — | EP | claimed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | claimed |
| EP-3012256-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | Shanghai Huilun Life Science & Technology Co., Ltd (CN) | 2016-04-27 | — | — | EP | claimed |
| CN-104981468-A | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-10-14 | — | — | CN | claimed |
| US-6805718-B2 | USING AROMATIC AMINE, NAPHTHOL OR AMINONAPHTHALENE AND ENZYME | NOVOZYMES A/S (DK) | 2004-10-19 | — | — | US | claimed |
| US-20030226215-A1 | Enzymatic method for textile dying | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-12-11 | — | — | US | claimed |
| WO-2003016615-A1 | SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1266068-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | Novozymes North America, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20010037532-A1 | Enzymatic method for textile dyeing | NOVOZYMES A/S (DK) | 2001-11-08 | — | — | US | claimed |
| US-6296672-B1 | PEROXIDASE, OXIDOREDUCTASE, LACCASE | NOVOZYMES A/S PATENTS (DK) | 2001-10-02 | — | — | US | claimed |
| WO-2001044563-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | NOVOZYMES NORTH AMERICA, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| JP-11171886-A | — | — | None | — | — | JP | disclosed |
| CN-121609673-B | PDE4 inhibitor and preparation method and application thereof | WUYI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-118290987-B | PCB (printed circuit board) inkjet printing anti-diffusion agent and preparation method and using method thereof | 珠海市板明科技有限公司 | 2026-05-01 | — | — | CN | disclosed |
| CN-120040757-A | Wear-resistant water-based alkyd resin and preparation method thereof | 山东齐鲁漆业有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3936192-B1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| CN-119264063-A | Preparation method of phenazine compound | 新乡医学院 | 2025-01-07 | — | — | CN | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118834600-A | PCB anti-diffusion agent and preparation method and application thereof | 松井新材料研究院(广东)有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240343706-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S. A. (PL) | 2024-10-17 | — | — | US | disclosed |
| CN-118290987-A | PCB (printed circuit board) inkjet printing anti-diffusion agent and preparation method and using method thereof | 珠海市板明科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118290987-A | PCB (printed circuit board) inkjet printing anti-diffusion agent and preparation method and using method thereof | 珠海市板明科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240109899-A1 | BENZOFURAN COMPOUNDS AS STING AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| CN-116606491-B | Anti-aging PE material and synthesis process thereof | 广东诚和信新材料有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-110997691-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-111051327-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-115318113-B | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2023-10-31 | — | — | CN | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | disclosed |
| CN-114105800-B | Preparation method of 2, 3-diaminomethyl benzoate | 杭州国瑞生物科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116655542-A | Dihydro quinolinone derivative, preparation method and application | 中山大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-116606491-A | Anti-aging PE material and synthesis process thereof | 广东诚和信新材料有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-3661910-B1 | NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3661910-B1 | NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023098699-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023098699-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-06-08 | — | — | WO | disclosed |
| CN-116134026-A | Triazole derivatives and their use as tankyrase inhibitors | 奥斯陆大学国家医院 | 2023-05-16 | — | — | CN | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| EP-4175952-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | Oslo Universitetssykehus HF (NO) | 2023-05-10 | — | — | EP | disclosed |
| EP-3676278-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-11608335-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115318113-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115023419-A | Cereblon-bound piperidine-2, 6-diones and methods of use thereof | 凯普托尔治疗学股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220249687-A1 | BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS | THE UNIVERSITY OF BATH (GB) | 2022-08-11 | — | — | US | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| EP-3990023-A1 | BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS | The University Of Bath (GB) | 2022-05-04 | — | — | EP | disclosed |
| EP-3642199-B1 | BENZOFURANS AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114105800-A | Preparation method of 2, 3-diaminobenzoic acid methyl ester | 杭州国瑞生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114105800-A | Preparation method of 2, 3-diaminobenzoic acid methyl ester | 杭州国瑞生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114105800-A | Preparation method of 2, 3-diaminobenzoic acid methyl ester | 杭州国瑞生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114026063-A | Bis (2-haloacetamido) -compounds useful as linkers and resulting products comprising antibodies, half-antibodies and antibody fragments | 巴斯大学 | 2022-02-08 | — | — | CN | disclosed |
| WO-2022008896-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. | GOLDING, LOUISE (GB) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022008896-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. | GOLDING, LOUISE (GB) | 2022-01-13 | — | — | WO | disclosed |
| EP-3936192-A1 | PYRROLOPYRAZOLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-09 | — | — | US | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| CN-113543852-A | Pyrrolopyrazole derivatives | 第一三共株式会社 | 2021-10-22 | — | — | CN | disclosed |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3878837-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | TOKUYAMA CORPORATION (JP) | 2021-08-12 | — | — | US | disclosed |
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | TOKUYAMA CORPORATION (JP) | 2021-08-12 | — | — | US | disclosed |
| CN-113166100-A | Immunomodulatory compounds | 达纳-法伯癌症研究所有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021105334-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105334-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-107089972-B | Preparation method of candesartan cilexetil | 浙江华海药业股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112789040-A | Transglutaminase 2(TG2) inhibitors | 思达利医药公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3816151-A1 | METHOD FOR PRODUCING ?-AZIDOANILINE DERIVATIVE OR ?, ?'-DIAZIDE DERIVATIVE | Tokuyama Corporation (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814330-A1 | IMMUNOMODULATORY COMPOUNDS | Dana-Farber Cancer Institute, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-11 | — | — | US | disclosed |
| US-10899774-B2 | IRAK4 modulators | GENENTECH, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| CN-112262124-A | Process for producing alpha-azidoaniline derivative or alpha, alpha' -diazide derivative | 株式会社德山 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020260514-A1 | BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS | THE UNIVERSITY OF BATH (GB) | 2020-12-30 | — | — | WO | disclosed |
| EP-3752498-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| CN-107922430-B | 2-substituted benzimidazole-4-formamide compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-04 | — | — | CN | disclosed |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200215042-A1 | NOVEL SUBSTITUTED PYRIDINYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200215042-A1 | NOVEL SUBSTITUTED PYRIDINYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3676278-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3661910-A1 | NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200172514-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | APOTEX INC. (CA) | 2020-06-04 | — | — | US | disclosed |
| EP-3658565-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3642199-A1 | BENZOFURANS AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-111051327-A | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200115388-A1 | IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| CN-110997691-A | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10556887-B2 | Processes for the preparation of Veliparib and intermediates thereof | APOTEX INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| CN-110770229-A | Benzofuran compounds as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| CN-110621652-A | Process for producing diaminobenzene compound | 株式会社德山 | 2019-12-27 | — | — | CN | disclosed |
| WO-2019157458-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190119257-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2019-04-25 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019046498-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019027856-A1 | NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019027856-A1 | NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-10196381-B2 | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD (CN) | 2019-02-05 | — | — | US | disclosed |
| US-10196381-B2 | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition containing the same, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD (CN) | 2019-02-05 | — | — | US | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| EP-3424909-A1 | A POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) INHIBITOR AND USES THEREFOR | Washington University (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3424909-A1 | A POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) INHIBITOR AND USES THEREFOR | Washington University (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018234343-A1 | BENZOFURANS AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| EP-3417850-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-12-26 | — | — | EP | disclosed |
| US-20180326100-A1 | Radiolabeled Tracers for Poly (ADP-RIBOSE) Polymerase-1 (PARP-1), Methods and Uses Therefor | WASHINGTON UNIVERSITY | 2018-11-15 | — | — | US | disclosed |
| EP-3089965-B1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | UNIV WASHINGTON (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3012256-B1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| EP-3012256-B1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECH CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9993570-B2 | Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor | WASHINGTON UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993570-B2 | Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor | WASHINGTON UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993570-B2 | Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor | WASHINGTON UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2018071761-A1 | MITOCHONDRIALLY TARGETED PARP INHIBITOR, AND USES THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180021311-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| EP-2970178-B1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN LA ROCHE (CH) | 2017-06-14 | — | — | EP | disclosed |
| EP-2970178-B1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN LA ROCHE (CH) | 2017-06-14 | — | — | EP | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-2708223-B1 | DYEING AGENT AND USE FOR SAME | AMANO ENZYME INC (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20160339124-A1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160339124-A1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160339124-A1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| EP-3089965-A1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | Washington University (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9453051-B2 | Cyclosporin derivatives | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160207909-A1 | Synthesis Method of Anti-Cancer Drug UK-1 and Derivatives Thereof | HUANG YUNG-TZUNG (TW) | 2016-07-21 | — | — | US | disclosed |
| US-20160207909-A1 | Synthesis Method of Anti-Cancer Drug UK-1 and Derivatives Thereof | HUANG YUNG-TZUNG (TW) | 2016-07-21 | — | — | US | disclosed |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3031802-A1 | PRODUCTION METHOD FOR 3, 3-DIMETHYL-3, 4-DIHYDRO-1H-QUINOXALINE-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | Santen Pharmaceutical Co., Ltd (JP) | 2016-06-15 | — | — | EP | disclosed |
| EP-3031802-A1 | PRODUCTION METHOD FOR 3, 3-DIMETHYL-3, 4-DIHYDRO-1H-QUINOXALINE-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | Santen Pharmaceutical Co., Ltd (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2016-06-09 | — | — | US | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| EP-3019482-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-05-18 | — | — | EP | disclosed |
| US-9334480-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334480-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334480-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-3012256-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | Shanghai Huilun Life Science & Technology Co., Ltd (CN) | 2016-04-27 | — | — | EP | disclosed |
| CN-103857657-B | Hete rocyclic derivatives and medicine | NIPPON SHINYAKU CO.,LTD. (JP) | 2016-04-20 | — | — | CN | disclosed |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2970178-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-9216968-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2746265-B1 | HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR | NIPPON SHINYAKU CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-9181218-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181218-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181218-B2 | Compounds for improved stem cell differentiation into hepatocytes | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| CN-104981468-A | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2015-10-14 | — | — | CN | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2318376-B1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150197726-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197726-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197726-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-07-16 | — | — | US | disclosed |
| WO-2015103526-A1 | RADIOLABELED TRACERS FOR POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1), METHODS AND USES THEREFOR | WASHINGTON UNIVERSITY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150183761-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183761-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183761-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150158840-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158840-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158840-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES | 2015-04-30 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2822956-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2014201972-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD AND USE THEREOF | 上海汇伦生命科技有限公司 (CN) | 2014-12-24 | — | — | WO | disclosed |
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140316104-A1 | CYCLOSPORIN DERIVATIVES | LEAD DISCOVER CENTER GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8846947-B2 | Benzimidazoles and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014140058-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140058-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014128669-A2 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-28 | — | — | WO | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2344475-B1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2746265-A1 | HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG | Nippon Shinyaku Co., Ltd. (JP) | 2014-06-25 | — | — | EP | disclosed |
| CN-103857657-A | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO LTD | 2014-06-11 | — | — | CN | disclosed |
| US-8740994-B2 | Dyeing agent and use for same | AMANO ENZYME INC. (JP) | 2014-06-03 | — | — | US | disclosed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| EP-2708223-A1 | DYEING AGENT AND USE FOR SAME | Amano Enzyme Inc. (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20140068875-A1 | DYEING AGENT AND USE FOR SAME | AMANO ENZYME INC (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8623858-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-07 | — | — | US | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130273568-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273568-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273568-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130261077-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134415-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-1957078-B1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2601188-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | disclosed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | disclosed |
| US-20130137674-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-05-30 | — | — | US | disclosed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123233-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | disclosed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377964-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8338594-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1863771-B1 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8288550-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2440542-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-8143279-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143279-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143279-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012018325-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| EP-2398794-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110201644-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| EP-2318376-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2315763-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2011035019-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7897775-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110021518-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331299-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124114-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1303631-B9 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-7781596-B1 | Substituted 2-phenylbenzimidazoles, the production thereof and their use | ABBOTT LABORATORIES (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781596-B1 | Substituted 2-phenylbenzimidazoles, the production thereof and their use | ABBOTT LABORATORIES (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1636216-B1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7741341-B2 | Benzimidazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-1303631-B1 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2170072-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010032461-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017401-A1 | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100029946-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | THERAVANCE, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-7622587-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| EP-2044062-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1957078-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1452528-B1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1899324-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| WO-2008015429-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015429-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| US-7294643-B2 | UK-1 analogues: methods of preparation and use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-18 | — | — | US | disclosed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007064932-A2 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-RE39608-E1 | Substituted benzimidazoles and their use as PARP inhibitors | ABBOTT GMBH & CO. KG (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127815-A2 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-7034048-B2 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-04-25 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| CN-1742007-A | Indole-derivative modulators of steroid hormone nuclear receptors | LILLY CO ELI (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1461035-A4 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| US-20050004188-A1 | UK-1 analogues: methods of preparation and use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-06 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479676-A1 | Benzimidazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| EP-0878740-B1 | Radiation sensitive polymer composition | TORAY INDUSTRIES (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6805718-B2 | USING AROMATIC AMINE, NAPHTHOL OR AMINONAPHTHALENE AND ENZYME | NOVOZYMES A/S (DK) | 2004-10-19 | — | — | US | disclosed |
| EP-1461035-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1452528-A1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6737421-B1 | 4-CARBOXYAMIDO SUBSTITUTED; NEURODEGENERATIVE DISEASES; NEURONAL DAMAGE | ABBOTT GMBH & CO. KG (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6696437-B1 | Heterocyclically substituted benzimidazoles, the production and application thereof | ABBOTT GMBH & CO. KG (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030226215-A1 | Enzymatic method for textile dying | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-12-11 | — | — | US | disclosed |
| EP-0974576-B1 | Method of producing benzamide derivatives | MITSUI CHEMICALS INC (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| US-20030180893-A1 | Biotransformation of biologically active compounds made of various classes of chemical substance by means of laccase and manganese peroxidase enzymes | ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-1342831-A2 | Enzymatic method for textile dyeing | Novozymes North America, Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003053344-A2 | SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0870082-B1 | ENZYMATIC METHOD FOR DYEING | NOVOZYMES NORTH AMERICA INC (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-0873444-B1 | ENZYMATIC METHOD FOR TEXTILE DYEING | NOVOZYMES NORTH AMERICA INC (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1303631-A2 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | Schauer, Frieder (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003016615-A1 | SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES | NOVOZYMES NORTH AMERICA, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1266068-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | Novozymes North America, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-0841924-B1 | BENZIMIDAZOLE COMPOUNDS | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6448271-B1 | SUCH AS 2-(PIPERIDIN-4-YL)BENZIMIDAZOLE-4-CARBOXAMIDE; INHIBITORS OF ENZYME POLY(ADP-RIBOSE)POLYMERASE; IMPROVED WATER SOLUBILITY | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-10 | — | — | US | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001098518-A2 | BIOTRANSFORMATION OF BIOLOGICALLY ACTIVE COMPOUNDS MADE OF VARIOUS CLASSES OF CHEMICAL SUBSTANCES BY MEANS OF LACCASE AND MANGANESE PEROXIDASE ENZYMES | GANOMYCIN GMBH (DE) | 2001-12-27 | — | — | WO | disclosed |
| CN-1325385-A | Gastrin and cholecystokinin receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-12-05 | — | — | CN | disclosed |
| US-6320078-B1 | CONVERTING BENZOIC ACID DERIVATIVE INTO BENZOYLIMIDAZOLE DERIVATIVE, REACTING BENZOYLIMIDAZOLE DERIVATIVE WITH PHENYLENEDIAMINE DERIVATIVE TO PREPARE SELECTIVELY MONOACYLATED PHENYLENEDIAMINE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2001-11-20 | — | — | US | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| US-20010037532-A1 | Enzymatic method for textile dyeing | NOVOZYMES A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| WO-2001074786-A1 | HETEROBIARYLSULPHONAMIDES AND THEIR USE AS PDE 7 INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2001-10-11 | — | — | WO | disclosed |
| US-6296672-B1 | PEROXIDASE, OXIDOREDUCTASE, LACCASE | NOVOZYMES A/S PATENTS (DK) | 2001-10-02 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001044563-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | NOVOZYMES NORTH AMERICA, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | disclosed |
| US-6090525-A | PHOTOSENSITIVE POLYIMIDE COATING AGENT COMPOSITION WITH BOTH GOOD VISCOSITY STABILITY AT ROOM TEMPERATURE WITH LAPSE OF TIME AND GOOD PHOTOSENSITIVE PERFORMANCE | TORAY INDUSTRIES, INC. (JP) | 2000-07-18 | — | — | US | disclosed |
| US-6036729-A | DYEING, SOAKING MATERIAL WITH NAPHTHOLS, HYDROGEN PEROXIDE AND ENZYMES OF PEROXIDASE OR OXIDASE | NOVO NORDISK A/S (DK) | 2000-03-14 | — | — | US | disclosed |
| EP-0974576-A2 | Method of producing benzamide derivatives | Mitsui Chemicals, Inc. (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0963192-A2 | DIAMINOBENZOIC ACID DERIVATIVES AS DYE PRECURSORS | NOVO NORDISK A/S (DK) | 1999-12-15 | — | — | EP | disclosed |
| US-5972042-A | DYEING SYSTEM WHICH COMPRISES ONE OR MORE MONO-, DI- OR POLYCYCLIC AROMATIC OR HETEROAROMATIC COMPOUNDS, AND HYDROGEN PEROXIDE SOURCE AND ENZYME EXHIBITING PEROXIDASE ACTIVITY OR ENZYME EXHIBITING OXIDASE ACTIVITY | NOVO NORDISK A/S (DE) | 1999-10-26 | — | — | US | disclosed |
| US-5925148-A | TREATING IN AQUEOUS DYE LIQUOR WITH SYSTEM COMPRISING SUBSTITUTED AROMATIC COMPOUND, HYDROGEN PEROXIDE SOURCE AND PEROXIDASE ENZYME AND/OR OXIDASE ENZYME | NOVO NORDISK A/S (DK) | 1999-07-20 | — | — | US | disclosed |
| JP-H11171886-A | PYPROLYLBENZIMIDAZOLE DERIVATIVE HAVING AMIDINE OR GUANIDINE IN SIDE CHAIN | MITSUI CHEM INC | 1999-06-29 | — | — | JP | disclosed |
| EP-0878740-A1 | Radiation sensitive polymer composition | TORAY INDUSTRIES, INC. (JP) | 1998-11-18 | — | — | EP | disclosed |
| EP-0873444-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | Novo Nordisk Biochem North America (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0870082-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| WO-1998015257-A1 | DIAMINOBENZOIC ACID DERIVATIVES AS DYE PRECURSORS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997023685-A1 | ENZYMATIC METHOD FOR TEXTILE DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023684-A1 | ENZYMATIC METHOD FOR DYEING | NOVO NORDISK BIOCHEM NORTH AMERICA, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | disclosed |
| US-5597921-A | ANTITUMOR AGENTS, TREATMENT OF LEUKEMIA | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0695754-A1 | INDOLO 2,3-b]QUINOXALINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1996-02-07 | — | — | EP | disclosed |
| US-5470867-A | Imidazoles and their salts having antagonistic activity to angiotesin II recetors | ROUSSEL-UCLAF (FR) | 1995-11-28 | — | — | US | disclosed |
| US-5389634-A | Treating arterial hypertension, relaxing uterus, prevention of post-angioplastic restenosis | ROUSSEL-UCLAF (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5338756-A | Angiotensin II receptor antagonists | ROUSSEL UCLAF (FR) | 1994-08-16 | — | — | US | disclosed |
| US-4769384-A | ANTIULCER AGENTS | NIPPON SHINYAKU CO. LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
| US-4769384-A | ANTIULCER AGENTS | NIPPON SHINYAKU CO. LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | ALDH1A1 1256/4885HSD17B10 2241/4885CFTR 1750/4885 |
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | ALDH1A1 2074/4885HSD17B10 3124/4885CFTR 732/4885 |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | ALDH1A1 1322/4885HSD17B10 2481/4885CFTR 778/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | ALDH1A1 1283/4885HSD17B10 2318/4885CFTR 1910/4885 |
| US-20180021311-A1 | TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | DHODH, DHFR, DPYD | ALDH1A1 109/4885HSD17B10 314/4885CFTR 4402/4885 |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885HSD17B10 2195/4885CFTR 2812/4885 |
| US-10899774-B2 | IRAK4 modulators | IRAK4, IRAK1, IRAK2 | ALDH1A1 1862/4885HSD17B10 2267/4885CFTR 1860/4885 |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | ALDH1A1 1275/4885HSD17B10 3386/4885CFTR 472/4885 |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | ALDH1A1 2449/4885HSD17B10 2131/4885CFTR 4714/4885 |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | ALDH1A1 1275/4885HSD17B10 3386/4885CFTR 472/4885 |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | ALDH1A1 2998/4885HSD17B10 2581/4885CFTR 1383/4885 |
| US-10556887-B2 | Processes for the preparation of Veliparib and intermediates thereof | PARP1, PARP3, PARP11 | ALDH1A1 755/4885HSD17B10 1996/4885CFTR 3209/4885 |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HSD17B10 1305/4885CFTR 890/4885 |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | ALDH1A1 1275/4885HSD17B10 3386/4885CFTR 472/4885 |
| US-20220249687-A1 | BIS(2-HALOACETAMIDO)-COMPOUNDS FOR USE AS LINKING AGENTS AND RESULTANT PRODUCTS WHICH COMPRISE ANTIBODIES, HALF-ANTIBODIES AND ANTIBODY FRAGMENTS | PAICS, PA2G4, GSTM2 | ALDH1A1 307/4885HSD17B10 2983/4885CFTR 2218/4885 |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | HTR4, HTR1A, HTR5A | ALDH1A1 1458/4885HSD17B10 3388/4885CFTR 433/4885 |
| US-20200172514-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | PARP1, PARP3, PARP11 | ALDH1A1 755/4885HSD17B10 1996/4885CFTR 3209/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HSD17B10 1305/4885CFTR 890/4885 |
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885HSD17B10 1604/4885CFTR 366/4885 |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | ALDH1A1 4307/4885HSD17B10 2339/4885CFTR 4618/4885 |
| US-20150197726-A1 | COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES | SLC10A1, HNF4A, CYP7A1 | ALDH1A1 7/4885HSD17B10 59/4885CFTR 151/4885 |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ALDH1A1 364/4885HSD17B10 179/4885CFTR 619/4885 |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ALDH1A1 364/4885HSD17B10 179/4885CFTR 619/4885 |
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | ALDH1A1 2253/4885HSD17B10 3360/4885CFTR 472/4885 |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | ALDH1A1 1717/4885HSD17B10 955/4885CFTR 2248/4885 |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | ALDH1A1 1877/4885HSD17B10 825/4885CFTR 3936/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ALDH1A1 364/4885HSD17B10 179/4885CFTR 619/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | ALDH1A1 2476/4885HSD17B10 2947/4885CFTR 898/4885 |
| US-20160207909-A1 | Synthesis Method of Anti-Cancer Drug UK-1 and Derivatives Thereof | ALDH7A1, ADH1A, ALDH1A1 | ALDH1A1 3/4885HSD17B10 717/4885CFTR 4740/4885 |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | ALDH1A1 1444/4885HSD17B10 1805/4885CFTR 1009/4885 |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | ALDH1A1 156/4885HSD17B10 2043/4885CFTR 1122/4885 |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ALDH1A1 364/4885HSD17B10 179/4885CFTR 619/4885 |
| US-20110201644-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | HTR4, HTR5A, HTR1A | ALDH1A1 2074/4885HSD17B10 3124/4885CFTR 732/4885 |
| US-20160159776-A1 | BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF | PARP2, PARP1, PARP15 | ALDH1A1 231/4885HSD17B10 1930/4885CFTR 1802/4885 |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | ALDH1A1 325/4885HSD17B10 3568/4885CFTR 3620/4885 |
| US-20150119426-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | ALDH1A1 2561/4885HSD17B10 2635/4885CFTR 236/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885HSD17B10 1604/4885CFTR 366/4885 |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | ALDH1A1 156/4885HSD17B10 2043/4885CFTR 1122/4885 |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ALDH1A1 364/4885HSD17B10 179/4885CFTR 619/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885HSD17B10 2195/4885CFTR 2812/4885 |
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | ALDH1A1 2007/4885HSD17B10 960/4885CFTR 2234/4885 |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | ALDH1A1 1877/4885HSD17B10 825/4885CFTR 3936/4885 |
| US-20180326100-A1 | Radiolabeled Tracers for Poly (ADP-RIBOSE) Polymerase-1 (PARP-1), Methods and Uses Therefor | PARP4, PARP1, PARP11 | ALDH1A1 671/4885HSD17B10 4300/4885CFTR 4104/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885HSD17B10 2195/4885CFTR 2812/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ALDH1A1 1444/4885HSD17B10 1805/4885CFTR 1009/4885 |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | ALDH1A1 3768/4885HSD17B10 4535/4885CFTR 1851/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | ALDH1A1 451/4885HSD17B10 2834/4885CFTR 131/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | ALDH1A1 360/4885HSD17B10 1809/4885CFTR 2897/4885 |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | ALDH1A1 95/4885HSD17B10 199/4885CFTR 3051/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885HSD17B10 1305/4885CFTR 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.